A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

January 27, 2020

Study Completion Date

December 31, 2023

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

Blinatumomab

Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia

Trial Locations (1)

Massachusetts general Hospital, Boston